Vaccine sales recover at GSK in Q3, but lockdown fears weigh on sharesGlaxoSmithKline saw a recovery in its vaccine sales in the third quarter after a big hit in the Share XVaccine sales recover at GSK in Q3, but lockdown fears weigh on shareshttps://pharmaphorum.com/news/vaccine-sales-recover-at-gsk-in-q3-but-lockdown-fears-weigh-on-shares/
Novartis on point in EU for asthma triple as CHMP backs EnerzairNovartis has moved a step closer to EU approval of its three-drug asthma therapy Enerzair Breezhaler, and now Share XNovartis on point in EU for asthma triple as CHMP backs Enerzairhttps://pharmaphorum.com/news/novartis-on-point-in-eu-for-asthma-triple-as-chmp-backs-enerzair/
Shingrix and Trelegy shield GSK from Advair falloutGlaxoSmithKline is expecting flat earnings this year, having earlier forecast a decline, as rising sales of new drugs Share XShingrix and Trelegy shield GSK from Advair fallouthttps://pharmaphorum.com/news/gsk-advair-shingles-vaccine-trelegy/
Trial could unlock asthma use for GSK’s TrelegyGlaxoSmithKline CEO Emma Walmsley has been predicting big things for respiratory triple therapy Trelegy in the next couple Share XTrial could unlock asthma use for GSK’s Trelegyhttps://pharmaphorum.com/news/trial-could-unlock-asthma-use-for-gsks-trelegy/
